Lyra Therapeutics Inc
LYRA1.820USD
+0.040+2.25%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.99MMarket Cap
LossP/E TTM
More Details of Lyra Therapeutics Inc Company
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Lyra Therapeutics Inc Info
Ticker SymbolLYRA
Company nameLyra Therapeutics Inc
IPO dateMay 01, 2020
CEOPalasis (Maria)
Number of employees30
Security typeOrdinary Share
Fiscal year-endMay 01
Address480 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16173734600
Websitehttps://lyratherapeutics.com/
Ticker SymbolLYRA
IPO dateMay 01, 2020
CEOPalasis (Maria)
Company Executives of Lyra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Executive Chairman, President, Chief Executive Officer
Executive Chairman, President, Chief Executive Officer
--
-22000.00%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Mr. W. Bradford Smith
Mr. W. Bradford Smith
Independent Director
Independent Director
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Executive Chairman, President, Chief Executive Officer
Executive Chairman, President, Chief Executive Officer
--
-22000.00%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Mr. W. Bradford Smith
Mr. W. Bradford Smith
Independent Director
Independent Director
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
9.87%
North Bridge Venture Partners
6.64%
Ikarian Capital LLC
1.19%
Citadel Advisors LLC
1.10%
Nantahala Capital Management, LLC
0.71%
Other
80.50%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
9.87%
North Bridge Venture Partners
6.64%
Ikarian Capital LLC
1.19%
Citadel Advisors LLC
1.10%
Nantahala Capital Management, LLC
0.71%
Other
80.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
10.56%
Venture Capital
6.64%
Hedge Fund
3.03%
Individual Investor
0.62%
Investment Advisor
0.34%
Research Firm
0.13%
Other
78.70%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
160
367.18K
20.69%
-703.20K
2025Q3
166
629.46K
38.28%
-484.72K
2025Q2
168
643.63K
40.27%
-545.91K
2025Q1
169
680.57K
41.01%
-508.15K
2024Q4
169
34.27M
52.36%
-23.86M
2024Q3
170
41.74M
67.36%
-17.33M
2024Q2
155
41.35M
70.46%
-15.27M
2024Q1
137
54.47M
94.92%
+4.29M
2023Q4
113
50.90M
93.69%
+8.93M
2023Q3
96
40.42M
84.31%
-314.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
127.62K
7.19%
+1.90K
+1.51%
Sep 30, 2025
North Bridge Venture Partners
117.77K
6.64%
--
--
Mar 18, 2025
Ikarian Capital LLC
21.16K
1.19%
--
--
Sep 30, 2025
Citadel Advisors LLC
19.48K
1.1%
+19.48K
--
Sep 30, 2025
Nantahala Capital Management, LLC
12.56K
0.71%
+12.56K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
10.99K
0.62%
--
--
Sep 30, 2025
Waksal (Harlan W)
10.74K
0.61%
--
--
Mar 18, 2025
BlackRock Institutional Trust Company, N.A.
1.69K
0.1%
--
--
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.27K
0.07%
-2.11K
-62.49%
Dec 31, 2025
RBC Capital Markets Wealth Management
1.20K
0.07%
+224.00
+23.07%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
ProShares Hedge Replication ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 19, 2025
Merger
50→1
Date
Ex-dividend Date
Type
Ratio
May 19, 2025
Merger
50→1
